4th Jun 2021 13:39
Ap19
FORM 8.3
IRISH TAKEOVER PANEL
DISCLOSURE UNDER RULE 8.3 OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER RULES, 2013
DEALINGS BY PERSONS WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE
1. KEY INFORMATION
Name of person dealing (Note 1) | J.P. Morgan Securities LLC |
Company dealt in | Xeris Pharmaceuticals, Inc. |
Class of relevant security to which the dealings being disclosed relate (Note 2) | $0.001 common stock |
Date of dealing | 03 June 2021 |
2. INTERESTS AND SHORT POSITIONS
(a) Interests and short positions (following dealing) in the class of relevant security dealt in (Note 3)
| Long | Short | ||||
| Number |
| (%) | Number |
| (%) |
(1) Relevant securities | 3,727,616 5.62
| 739,231 1.11
| ||||
(2) Derivatives (other than options) | 595,172 0.90
|
| ||||
(3) Options and agreements to purchase/sell |
|
| ||||
Total | 4,322,788 6.52
| 739,231 1.11
| ||||
Ap20
1. DEALINGS (Note 4)
(a) Purchases and sales
Purchase/sale |
Number of relevant securities |
Price per unit (USD)
(Note 5) |
Purchase (Loan return)
Purchase(New Borrow)
Purchases Purchases Purchases Purchases Purchases Purchases Purchases Purchases
Sales Sales Sales Sales Sales Sales Sales Sales Sales Sales Sales Sales Sales Sales Sales Sales Sales Sales Sales Sales Sales Sales Sales Sales Sales Sales Sales Sales Sales Sales Sales Sales Sales Sales Sales | 100
22,900
100 28 100 100 90 505 87 100
2 3 3 10 3 7 4 8 1 11 1 1 6 1 1 1 2 200 1 28 56 1 200 180 1 1 505 174 15 8 1 5 8 1 200 | N/A
N/A
3.6800 USD 3.6273 USD 3.5700 USD 3.5602 USD 3.5522 USD 3.5160 USD 3.4980 USD 3.2500 USD
3.8900 USD 3.8500 USD 3.8467 USD 3.8400 USD 3.8367 USD 3.8300 USD 3.8250 USD 3.8150 USD 3.8100 USD 3.7873 USD 3.7800 USD 3.7700 USD 3.7483 USD 3.7400 USD 3.7300 USD 3.7100 USD 3.7075 USD 3.6800 USD 3.6700 USD 3.6621 USD 3.6273 USD 3.6100 USD 3.5700 USD 3.5522 USD 3.5500 USD 3.5300 USD 3.5160 USD 3.4980 USD 3.4927 USD 3.4913 USD 3.4900 USD 3.4600 USD 3.4575 USD 3.4500 USD 3.2500 USD |
(b) Derivatives transactions (other than options transactions)
Product name, e.g. CFD | Nature of transaction (Note 6) | Number of relevant securities (Note 7) | Price per unit (USD) (Note 5) |
Equity Swap |
|
|
|
(c) Options transactions in respect of existing relevant securities
(i) Writing, selling, purchasing or varying
Product name, e.g. call option | Writing, selling, purchasing, varying etc. | Number of securities to which the option relates (Note 7) | Exercise price | Type, e.g. American, European etc. | Expiry date | Option money paid/received per unit (Note 5) |
|
|
|
|
|
|
|
(ii) Exercising
Product name, e.g. call option | Number of securities | Exercise price per unit (Note 5) |
|
|
|
(d) Other dealings (including transactions in respect of new securities) (Note 4)
Nature of transaction (Note 8) | Details | Price per unit (if applicable) (Note 5) |
|
|
|
Ap21
2. OTHER INFORMATION
Agreements, arrangements or understandings relating to options or derivatives
Full details of any agreement, arrangement or understanding between the person disclosing and any other person relating to the voting rights of any relevant securities under any option referred to on this form or relating to the voting rights or future acquisition or disposal of anyrelevant securities to which any derivative referred to on this form is referenced. If none, this should be stated.
None
Is a Supplemental Form 8 attached? (Note 9) NO
Date of disclosure | 04 June 2021 |
Contact name | Alwyn Basch |
Telephone number | 0207 742 7407 |
If a connected EFM, name of offeree/offeror with which connected | N/A |
If a connected EFM, state nature of connection (Note 10) | N/A |
Related Shares:
Xeris Biopharma